

## **Research Article**

### **Comparative analysis of anthropometric parameters and lipid profile of type 2 diabetic patients in south west Punjab.**

**Arun Kumar Maria<sup>1</sup>, Khushboo Verma<sup>2</sup>, Satwant Kumar<sup>3</sup>, Vitull K Gupta<sup>4</sup>, Mohnish Kumar<sup>5</sup>**

<sup>1</sup> Professor, Department of Medicine, Adesh Institute of Medical Sciences and Research (AIMSR) Bathinda 151101, India.

<sup>2</sup> Ex Intern, Rabindra Nath Tagore Medical College and Hospital, Udaipur 313001, India

<sup>3</sup> Ex Intern AIMSR, Bathinda (presently Lab of Neuro- and Psychophysiology, KU Leuven, Belgium)

<sup>4</sup> Associate Professor (Department of Medicine), AIMSR, Bathinda

<sup>5</sup> Ex Intern, AIMSR, Bathinda India.

#### **\*Corresponding author**

Arun Kumar Maria

Email: [cooldoctor5@yahoo.co.in](mailto:cooldoctor5@yahoo.co.in)

---

**Abstract:** The objective of present study is to investigate the effectiveness of multiple adiposity indices to predict the hypertension, dyslipidemia and hyperuricemia in the north Indian type-2 diabetic patients. In this study 128 women and 269 men type-2 diabetic patients were recruited. Data was collected through clinical evaluation and laboratory investigations. Body weight and height, waist circumference (WC), and hip circumference (HC) were measured. Whereas, body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) were calculated. Blood pressure (BP), fasting lipid profiles, and glucose and urine acid levels were evaluated. It is found that the Mean BMI for females was 28.62 (SD 5.57) kg/m<sup>2</sup> and for males was 28.50 (SD 5.27) kg/m<sup>2</sup>. Whereas, mean WHR for females was 0.96 (SD 0.09) kg/m<sup>2</sup> and for males was 1.05 (SD 0.06) kg/m<sup>2</sup> and mean WHtR for females was 0.60 (SD 0.10) kg/m<sup>2</sup> and for males was 0.58 (SD 0.12) kg/m<sup>2</sup>. Receiver operating characteristic (ROC) curve analysis showed that WHtR is the best predictor for the classifying hypertension and dyslipidemia. Whereas, BMI is effective in predicting hyperuricemia in type-2 diabetic patients. Amongst type-2 diabetic patients of north Indian region WHtR is found to be the best predictor of dyslipidemia and hypertension.

**Keywords:** Metabolic Syndrome, Waist to height ratio, hyperuricemia, dyslipidemia, diabetes.

---

#### **INTRODUCTION**

The latest data on global burden of non-communicable diseases points towards rising trends of obesity in all age groups as well as across both sexes [1]. There is preponderance of metabolic and cardiovascular diseases increasing morbidity and mortality. The metabolic syndrome (MetS) is the co-existence of statistically significant "metabolic" risk factors, such as visceral obesity, dyslipidemia, hyperglycemia and hypertension. These factors appear to advance the development of atherosclerotic cardiovascular diseases (ASCVD) [2]. Several terms have been used to describe these constellation of features such as- Syndrome X (3), deadly quartet (4), insulin resistance syndrome [5,6] and the hypertriglycericemic waist [7]. Reaven was the first to put forward the concept of 'syndrome X', (which he later renamed MetS) [6] In our study, we examined the above mentioned risk factors in the patients who were already diagnosed with type 2 DM.

The metabolic syndrome has become the foremost public health threat in the contemporary

times[8]. The escalating burden of obesity is the impelling force behind its pervasiveness [9,10]. However, the more intriguing factor is the ethnic variation in the pathogenesis, disease presentation and treatment strategies. The first formal definition was proposed by a consultation group of WHO in 1999 and had insulin resistance, impaired glucose tolerance or diabetes as essential components.[11]. Owing to insufficient evidence and the ethnic variations, the definition of metabolic syndrome has still remained debatable ever since [12]. Another major criteria emerged from the National Cholesterol Education Program (NCEP) Expert Panel in 2001. Unlike the WHO criteria, according to the US National Cholesterol Education programme : Adult Treatment panel III (NCEP : ATP III) criteria, the demonstration of insulin resistance was not necessary, rather the presence of any three out five factors i.e. abdominal obesity, elevated triglyceride, reduced HDL, elevated fasting glucose and elevated blood pressure.. In 2005, the International Diabetes Federation (IDF) [13] and American Heart Association / National Heart Lung and Blood Institute (AHA/ NHLBI) endeavored to resolve the differences

in the clinical definitions. The IDF introduced abdominal obesity as a prerequisite of the diagnosis of MetS, with particular emphasis on waist measurement as a simple screening tool that was also adopted by AHA/NHLBI [6]. The remaining four components of MetS remained same as in the AHA/NHLBI, although abdominal obesity was defined differently. Currently, the two most widely used definitions are those of the NCEP: ATP III and IDF specifically focusing on waist circumference as a surrogate measure of central obesity. In contrast, the other definitions from WHO; the European Group for the study of Insulin Resistance (EGIR), and the National Cholesterol Education Program Adult Treatment Panel III (NCEP:ATPIII), the American Association of Clinical Endocrinology (AACE) definitions are all largely focused on insulin resistance are all largely focused on insulin resistance.

The physique of a patient with metabolic syndrome has constantly been a debatable theme for the healthcare researchers as well as the physicians. The Lancet expressed the build of a diabetic patient as “a roundedness of the body contour, a tendency to obesity, a smooth skin with fine hair and short tapering limbs with small hands and feet” [14].

This implies that not only adiposity, but also the pattern of fat distribution is significant. Upper body obesity has been held responsible for insulin resistance. Excess upper body fat is distributed either as extra peritoneal (visceral) or subcutaneous deposits. There are contradictory views regarding which of the two is linked with insulin resistance [15-17]. However, both can be collectively estimated clinically, by documenting the waist circumference as done in our study. Additionally, we included parameters like waist to hip ratio and waist to height ratio in our study. These parameters are of particular concern in a population group like in our study since the Asians exhibit the metabolic syndrome even with moderate degree of abdominal obesity [18, 19]. Thus, the Asians are proposed to be inherently insulin resistant [20]. Hence, as mentioned earlier, the inclusion of different cut-off points for abdominal obesity by IDF holds good and has been considered in the study.

We hereby intend to investigate the effectiveness of multiple adiposity indices to predict the presence of various components of metabolic syndrome namely - hypertension, dyslipidemia and hyperuricemia.

Variations in the adiposity are associated with changes in lipoproteins –high triglycerides (TG), low high density lipoprotein (HDL), increased coronary heart disease and non-insulin dependent diabetes mellitus (NIDDM) [21, 22]. Hence, fasting lipid profiles, glucose and urine acid levels were evaluated during the study period.

The Joint Statement of the IDF and NHLBI mentioned that, it is a key concern to consider the applicability of the criteria amongst the different ethnic groups [11]. Thus, it is essential to conduct studies in specific ethnic groups and record the findings of the particular geographical and ethnic groups. Our study focused over the north Indian diabetic patients.

The Joint Statement also calls attention to the compilation of evidence based cross-sectional and longitudinal data regarding degree of predisposition to CVD and type 2 diabetes mellitus with those showing above cut-off values of waist circumference. Additionally, it also promotes the studies exploring the relation of waist circumference thresholds to the metabolic risks and cardiovascular outcomes [11, 23]. Our study is an attempt to depict the extent of the disease in the specific geographical niche with the demonstration of various adiposity and metabolic indicators. Moreover, we aim to contribute to the ethnic specific information in the same regard.

#### **MATERIAL AND METHODS**

Three hundred and ninety seven (397) men (mean age 53.94 yrs) and women (mean age 51.05 yrs), all known patients of type 2 diabetes were recruited for the study. The patients with previously confirmed severe medical diseases, such as cancer, stroke and heart failure were excluded. All the participants gave written informed consent. The study was approved by the institute ethics committee

The patients, who were attending the Diabetes Clinic of the hospital between January 2012 and July 2013 were examined for this study. The patient confidentiality was assured by coding the patients' information and removing the identifiable personal data before data compilation. All the data was part of routine base line and follow up measurements of these patients. The anthropometric measurements, physical examination findings and blood pressure measurements were recorded at the same time. The blood sample (venous) were taken after overnight fasting ( $\geq 10$  h) along with the urine for biochemical analysis.

Body weight and height were recorded with the subjects dressed in minimal light clothing and without wearing the shoes. The waist circumference was measured from the center point of the distance between iliac crest and the lower most margins of the ribs. The hip circumference was measured between the maximum girths of the buttocks. The mean of three recording was taken from each site for the further calculations. The BMI was calculated as weight (in kilograms)/ height (in meters) squared. Similarly, WHR and WHtR were calculated as ratio of waist to hip and waist to height respectively.

Hypertension was defined by the ongoing use of antihypertensive treatment with systolic blood

pressure of  $\geq 140$  mm Hg, or diastolic blood pressure of  $\geq 90$  mm Hg (24). As per NCEP ATP III criteria (2), the subjects were classified dyslipidemia when presented with one or more of the following including: plasma cholesterol (TC)  $\geq 6.22$  mmol/L (240 mg/dl), triglycerides (TG)  $\geq 2.26$  mmol/L (200 mg/dl), LDLc  $\geq 4.14$  mmol/L (160 mg/dl), or HDLc  $< 1.03$  mmol/L (40 mg/dl). Hyperuricemia was diagnosed by serum uric acid  $\geq 420$   $\mu$ mol/l (7.0 mg/dl) in men, or  $\geq 350$   $\mu$ mol/l (6.0 mg/dl) in women [25].

The venous blood samples collected from subjects were centrifuged; the plasma was separated and used for further analysis. The serum total cholesterol (TC), triglycerides (TG) and HDL were measured by enzymatic calorimetric method and serum LDL were calculated by using Friedewald's formula i.e.  $LDL = TC - HDL - TG/5.0$  (mg/dL) [26]. The glucose oxidase method was used to detect glucose and the serum uric acid (UA) was measured by the enzymatic colorimetric method.

The data analysis was performed using R, an open source statistical programming environment for linear regression analysis and to generate logistic regression models, as described in detail previously [27]. The area under the receiver's operating characteristic curve (AUC) was used to compare the predictive ability of anthropometric and biochemical measurements of metabolic abnormalities. The AUC is a measure of the degree of separation between case and

control subjects [28, 29]. We used Student's t-test or -chi-square test for comparing the characteristics in the study population and the anthropometric parameters, and P-values less than 0.05 (two-tailed) were considered to be significant.


## RESULTS

Table 1 summarizes the characteristics of the subjects. The average age of the men in the study was 53.94 yrs which was higher than the average age of the women included in the study that is 51.05yrs. During the study, it was observed that the men have higher WHR and WC in comparison to the fairer sex.

The women patients with type-2 diabetes tend to have more incidence of hyperuricemia (18.7% vs. 12.2%). Conversely, men are more prone to both dyslipidemia (71.2% vs. 62.0%) and hypertension (56.6% vs. 39.6%).

WHR is the best predictor for forecasting the development of dyslipidemia (as depicted in Receiver Operating Characteristic (ROC) curve analysis in Figure 1.

In comparison to BMI, the WHR was found to be more effective in predicting dyslipidemia in type-2 diabetic patients (shown in Figure 2 and 3). WHtR is overall best suited for predicting hypertension and dyslipidemia. While, BMI predicted hyperuricemia effectively as shown in Table 2.



**Fig- 1: Receiver operating characteristic (ROC) curve showing area under the curve for waist to height ratio (WHtR) for dyslipidemia**




Fig- 2: Receiver operating characteristic (ROC) curve showing area under the curve for body mass index (BMI) for dyslipidemia.




Fig- 3: Receiver operating characteristic (ROC) curve showing area under the curve for waist to hip ratio (WHR) for dyslipidemia.

Table 1: Characteristics of subjects in type-2 diabetes patients

	Female		Male	
	Mean	SD	Mean	SD
Age, year	51.05	(14.17)	53.94	(13.3)
<b>Anthropometric measurements</b>				
BMI, kg/m <sup>2</sup>	28.62	(5.57)	28.50	(5.27)
Waist circumference(cm)	95.60	(17.55)	97.61	(18.17)
Hip circumference, cm	99.43	(17.95)	97.0	(16.56)
Waist to hip ratio	0.96	(0.09)	1.05	(0.06)
Waist to height ratio	0.60	(0.10)	0.58	(0.12)
<b>Biochemical indicators</b>				
Total cholesterol (mg/dL)	236.50	(54.68)	223.08	(57.28)
LDLc (mg/dL)	151.74	(45.03)	135.48	(45.82)
HDLc (mg/dL)	39.98	(19.69)	39.25	(18.20)
Triglycerides (mg/dL)	205.12	(105.15)	176.97	(58.46)
BUN (mg/dL)	11.40	(5.77)	12.05	(5.16)
Hemoglobin (mg/dL)	11.37	(1.59)	12.35	(2.07)
HbA1c levels	8.34	(1.10)	7.8	(2.0)
Fasting Blood Glucose (mg/dL)	156.27	(43.55)	157.21	(46.45)
Random Blood Glucose (mg/dL)	176.47	(70.41)	159.29	(56.16)
<b>Blood Pressure</b>				
Systolic (mmHg)	126	(28)	128	(26)
Diastolic (mmHg)	86	(23)	84	(14)

**Table 2: The area under the curves for each indices for the presence of the hyperuricemia, hypertension and dyslipidemia in type-2 diabetes patients.**

	Hyperuricemia	Dyslipidemia	Hypertension
WC	0.56	0.63	0.62
HC	0.62	0.54	0.61
BMI	0.66	0.64	0.66

WC = Waist circumference (cm), HC = Hip circumference (cm), BMI = Body Mass Index

## DISCUSSION

The primary aim while dealing with the people diagnosed with diabetes mellitus is to reduce the underlying risk factors which subsequently lead to the development of the metabolic syndrome. Furthermore, the morbidity risks arising due to both should be taken into consideration. Therefore, such individuals need to be categorized according to the 10 year risk [2]. The Framingham Risk Scoring should be estimated to gauge 10 year risk of CAD development [2].

In our study, the men were found to have higher WHR and WC in comparison to the women. It is significant to understand the sex differences while examining the various parameters related to the metabolic syndrome. This is indicated as there are significant morbidity implications in terms of CAD risk. The current guidelines for primary prevention of CAD favor more insistent therapy for the men then the women [30-32]. Earlier studies in the general population indicate that CAD has onset in later ages in the women as compared to the men [33, 34]. Conversely, diabetes signifies greater risk of CAD in the women [35, 36]. Thus, we studied the two sexes, separately in terms of various risk factors and predictors of the severity of the disease.

The mean BMI were recorded as 28.62 and 28.50 in female and male subjects respectively. Though the Expert Consultation Group by WHO agreed that a portion of Asian population has a higher degree of predisposition of diabetes and cardiovascular disease even at the WHO cut-off point for overweight ( $\geq 25$ ), yet the cutoff points shall remain the same for the international references [37]. Thus, by the WHO criteria both the sexes were overweight.

In our study it was found that the women with type-2 diabetes tend to have more incidence of hyperuricemia (18.7% vs. 12.2%). Hyperuricemia, besides being an element of metabolic syndrome, additionally worsens the insulin resistance by affecting the insulin stimulated glucose uptake [38]. Recently, meta-analyses expressed that elevated serum uric acid level is an independent risk factor for diabetes mellitus [39, 40]. Hyperuricemia by causing inhibition of nitric oxide leads to the advancement of the vascular lesions [38]. Thus, from the perspective of ascertaining the cardiovascular morbidity and mortality serum uric acid levels should be estimated in a diabetic patient.

On the other hand, our study concluded that the men were more prone to both dyslipidemia (71.2% vs. 62.0%) and hypertension (56.6% vs. 39.6%). Dyslipidemia is frequent in diabetes; and both insulin deficiency and insulin resistance are influenced by it. [41]. Hence, there occurs an atherogenic dyslipidemia which entails a summation of the lipoprotein abnormalities – elevated serum triglycerides, apo-B, increased small LDL particles and reduced HDL-C [2]. Elevated plasma glucose level additionally predisposes to atherosclerosis by various mechanisms [42]. It is a significant issue to consider the sex of the individual as the women suffering from type 2 DM is more likely to have higher levels of triglycerides [43]. This implies that the diabetic female is predisposed to more profound outcome risks.

The treatment strategies are affected by the pattern of dyslipidemia. In accordance with the ATP III guidelines [2], reduction of LDL-C is the primary focus. Furthermore, when the triglycerides  $\geq 200$ mg/dl, then the subsequent focus of the therapy is the reduction of triglycerides [2]. Statins is the first line of treatment as it reduces LDL-C as well as non-HDL-Cs; with the combined benefit of reducing the risk of cardiovascular events in the presence of metabolic syndrome [44]. The treatment currently advocated is the combination of statins with the fibrates and nicotinic acid as they reduce the cardiovascular events significantly [45-47]. For hypertension, the goal of an antihypertensive therapy is a blood pressure of  $<140/90$ mmHg (48). Nonetheless, the target in case of a diabetic patient, is set to be the optimum level of  $<130/80$ mmHg (24).

Particularly, in Indian context since a sizeable risk exists at a moderate degree of overweight [37], hence it is prudent for the patients as well as the clinicians to keep a strict vigilance over these anthropometric and laboratory parameters, as were measured in our study. This cautious approach is a cost effective alternative to initiating antihypertensive, especially when a large population exists in the pre-hypertensive category with diabetes or other metabolic risk factors. Various lifestyle amendments are recommended like increasing physical activity, alcohol restraint, salt reduction and dietary modification popularly summated as –Dietary Approaches to Stop Hypertension (DASH) [49].

Amongst the various anthropometric parameters the WHtR was found to be the best predictor

of dyslipidemia and hypertension. This is in agreement to the findings of previous studies [49-51]. It has been also regarded as the best predictor of undiagnosed diabetes, when compared to other anthropometric indicators such as BMI, waist circumference and waist to hip ratio [49]. In a comparative study with waist circumference, WHtR is better for predicting the cardiovascular and other outcomes [50]. It is proposed to be employed as a screening tool for those with high metabolic risks [50].

In a study, WHtR has even been proposed to be utilized as a global clinical tool; thereby suggesting a public health note “Keep your waist circumference to less than half of your height” [51].

It has been a fascinating quest to study the comparative predictive values of BMI and the other adiposity indicators. In the current study it was found that in comparison to BMI, WHR was more effective in predicting dyslipidemia in type-2 diabetic patients. On the other hand, BMI predicted hyperuricemia more effectively. These in disagreement to previous studies which indicate waist for height as a better indicator than BMI for various cardiovascular risk factors both in men and women [50-52].

Although, there is a universal understanding of plausible indicators, yet in the contemporary times it is imperative for clinicians to have a precise knowledge of the various anthropometric and laboratory parameters which are an early and unambiguous indicators. It is so since there is a rising incidence of diabetes and the metabolic syndrome. Another enthralling factor for early detection and management are the minimalistic interventions required in the initial stages of the disease. The health care professionals and clinicians play a major role in alerting and conveying this to the patient. The austere cost effective lifestyle measures that could be adopted should be suggested to the patients with high risk factors. It was experienced during the study that the general public awareness was not as appropriate as required for the enforcement of cumulative effort by both the patient and the clinician. As there is a massive upsurge in the incidence of obesity and metabolic syndrome, comprehensive approach for enhancing both the nutrition and physical activity targeting both the individual and the population are required [53].

Thus, by primary prevention the “bud can be nipped early”, before it acquires gigantic implications. Given that the syndrome and its repercussions are reversible in the early stages, health care professionals play a crucial role [54]. In any case, if the syndrome proceeds to irreversibility, all efforts should be made to prevent its further progression. In the interim, further studies should be encouraged to document the relative accuracies of bedside parameters in predicting metabolic disorders. It is also recommended to formulate consultation groups and release region and

ethnic specific guidelines to be uniformly adopted by the health care practitioners.

## REFERENCES

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al.; A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2224-60.
2. Mangat C, Goel NK, Walia DK, Agarwal N, Sharma MK, Kaur J, et al.; Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. *Diabetology & metabolic syndrome*. 2010;2:19.
3. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, et al.; Central role of the adipocyte in the metabolic syndrome. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*. 2001;49(1):119-26.
4. Grundy SM; Obesity, metabolic syndrome, and cardiovascular disease. *The Journal of clinical endocrinology and metabolism*. 2004;89(6):2595-600.
5. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A; Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-421.
6. Reaven GM; Role of insulin resistance in human disease (syndrome X): an expanded definition. *Annual review of medicine*. 1993;44:121-31.
7. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al.; Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? *Circulation*. 2000;102(2):179-84.
8. Kaplan NM; The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Archives of internal medicine*. 1989;149(7):1514-20.
9. DeFronzo RA, Ferrannini E; Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes care*. 1991;14(3):173-94.
10. Stern MP; The insulin resistance syndrome: the controversy is dead, long live the controversy! *Diabetologia*. 1994;37(9):956-8.
11. Alberti KG, Zimmet PZ; Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO

- consultation. *Diabetic medicine : a journal of the British Diabetic Association*. 1998;15(7):539-53.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.; Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. *Critical pathways in cardiology*. 2005;4(4):198-203.
  13. Alberti KG, Zimmet P, Shaw J; Group IDFETFC. The metabolic syndrome--a new worldwide definition. *Lancet*. 2005;366(9491):1059-62.
  14. Sun K, Ren M, Liu D, Wang C, Yang C, Yan L; Alcohol consumption and risk of metabolic syndrome: A meta-analysis of prospective studies. *Clinical nutrition*. 2013.
  15. Brochu M, Starling RD, Tchernof A, Matthews DE, Garcia-Rubi E, Poehlman ET; Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. *The Journal of clinical endocrinology and metabolism*. 2000;85(7):2378-84.
  16. Raji A, Seely EW, Arky RA, Simonson DC; Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. *The Journal of clinical endocrinology and metabolism*. 2001;86(11):5366-71.
  17. Ross R, Freeman J, Hudson R, Janssen I; Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. *The Journal of clinical endocrinology and metabolism*. 2002;87(11):5044-51.
  18. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S; The metabolically obese, normal-weight individual revisited. *Diabetes*. 1998;47(5):699-713.
  19. Dvorak RV, DeNino WF, Ades PA, Poehlman ET; Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. *Diabetes*. 1999;48(11):2210-4.
  20. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM; Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. *The Journal of clinical endocrinology and metabolism*. 1999;84(7):2329-35.
  21. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE; Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. *Diabetes care*. 2002;25(7):1129-34.
  22. Feldman R, Sender AJ, Siegel AB; Difference in diabetic and nondiabetic fat distribution patterns by skinfold measurements. *Diabetes*. 1969;18(7):478-86.
  23. Maria AK, Maheshwari A, Gupta VK, Singh GP, Kumar S, Kapoor A; A Comparative Study of Cardiovascular Response to Isometric Exercise in Hypertensive and Healthy Normotensive Controls in South West Punjab. *Journal of Research in Medical Education & Ethics*. 2013;3(2).
  24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al; The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA : the journal of the American Medical Association*. 2003;289(19):2560-72.
  25. Feig DI, Kang DH, Johnson RJ; Uric acid and cardiovascular risk. *The New England journal of medicine*. 2008;359(17):1811-21.
  26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18(6):499-502.
  27. Schaul T, Bayer J, Wierstra D, Sun Y, Felder M, et al.; PyBrain. *Journal of Machine Learning Research*, 2010; 11: 743–746.
  28. Huang J, Ling CX; Using AUC and accuracy in evaluating learning algorithms. *IEEE Transactions on Knowledge and Data Engineering*. 2005;17(3):299-310.
  29. Kumar S, Rana ML, Verma K, Singh N, Sharma AK, Maria AK, et al.; PrediQt-Cx: post treatment health related quality of life prediction model for cervical cancer patients. *PloS one*. 2014;9(2).
  30. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al.; Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. *Journal of the American College of Cardiology*. 2011;57(12):1404-23.
  31. Mosca L, Barrett-Connor E, Wenger NK; Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. *Circulation*. 2011;124(19):2145-54.
  32. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al.; Aspirin for primary prevention of cardiovascular events in people with diabetes. *Journal of the American College of Cardiology*. 2010;55(25):2878-86.
  33. Liu PY, Death AK, Handelsman DJ; Androgens and cardiovascular disease. *Endocrine reviews*. 2003;24(3):313-40.
  34. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P; Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. *Monitoring trends and determinants in cardiovascular disease*. *Lancet*. 1999;353(9164):1547-57.
  35. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL; Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. *Archives of internal medicine*. 2003;163(14):1735-40.
  36. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nijpels G, et al.; Cardiovascular events in type

- 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. *European heart journal*. 2003;24(15):1406-13.
37. Consultation WHOE; Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363(9403):157-63.
38. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A; Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. *Journal of cardiology*. 2012;59(3):235-42.
39. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al.; Association between serum uric acid and development of type 2 diabetes. *Diabetes care*. 2009;32(9):1737-42.
40. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al.; High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PloS one*. 2013;8(2):e56864.
41. American Diabetes A; Diagnosis and Classification of Diabetes Mellitus. *Diabetes care*. 2011;34(Supplement\_1):S62-S9.
42. Aronson D, Rayfield EJ; How hyperglycemia promotes atherosclerosis: molecular mechanisms. *Cardiovascular diabetology*. 2002;1:1.
43. Gordon L, Ragoobirsingh D, Morrison EY, Choo-Kang E, McGrowder D, Martorell E; Lipid profile of type 2 diabetic and hypertensive patients in the jamaican population. *Journal of laboratory physicians*. 2010;2(1):25-30.
44. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J; Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. *Circulation*. 2001;104(25):3046-51.
45. Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. *Journal of cardiovascular risk*. 2000;7(5):339-45.
46. Canner PL, Furberg CD, Terrin ML, McGovern ME; Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). *The American journal of cardiology*. 2005;95(2):254-7.
47. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al.; Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). *The American journal of cardiology*. 2003;91(6):667-72.
48. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al.; Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42(6):1206-52.
49. Xu Z, Qi X, Dahl AK, Xu W; Waist-to-height ratio is the best indicator for undiagnosed type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2013;30(6):e201-7.
50. Ashwell M, Gunn P, Gibson S; Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obesity reviews : an official journal of the International Association for the Study of Obesity*. 2012;13(3):275-86.
51. Browning LM, Hsieh SD, Ashwell M; A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. *Nutrition research reviews*. 2010;23(2):247-69.
52. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *Journal of clinical epidemiology*. 2008;61(7):646-53.
53. Swinburn B, Egger G; Preventive strategies against weight gain and obesity. *Obesity reviews : an official journal of the International Association for the Study of Obesity*. 2002;3(4):289-301.
54. Ford ES, Giles WH, Mokdad AH; Increasing prevalence of the metabolic syndrome among u.s. Adults. *Diabetes care*. 2004;27(10):2444-9.